T-DM1 in the Neo-Adjuvant Treatment of HER2-Positive Breast Cancer: Impact of the KRISTINE (TRIO-021) Trial

Publisher： Bentham Science Publishers

E-ISSN： 1876-1038|12|3|216-222

ISSN： 1574-8871

Source： Reviews on Recent Clinical Trials, Vol.12, Iss.3, 2017-11, pp. : 216-222

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer

By Boyraz Baris   Sendur Mehmet A.N.   Aksoy Sercan   Babacan Taner   Roach Emir C.   Kizilarslanoglu Muhammet C.   Petekkaya Ibrahim   Altundag Kadri  

Current Medical Research and Opinion, Vol. 29, Iss. 4, 2013-04 ,pp. : 405-414

Informa Healthcare

Access to resources Recommend Favorite

Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T‐DM1) vs. treatment of physician's choice in previously treated HER2‐positive advanced breast cancer

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 139, Iss. 10, 2016-11 ,pp. : 2336-2342

John Wiley & Sons Inc

Access to resources Recommend Favorite

Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer

By Haq Bushra   Geyer Charles E  

Women's Health, Vol. 5, Iss. 2, 2009-03 ,pp. : 135-147

Future Medicine

Access to resources Recommend Favorite

Adjuvant Chemotherapy for the Treatment of HER2-Positive Early Breast Cancer

By  

Oncology, Vol. 77, Iss. 1, 2010-02 ,pp. : 14-17

Karger

Access to resources Recommend Favorite

Neoadjuvant Therapy for HER2-positive Breast Cancer

By  

Reviews on Recent Clinical Trials, Vol. 12, Iss. 2, 2017-05 ,pp. : 81-92

Bentham Science Publishers

Access to resources Recommend Favorite